The most MSLN over-expressing tumor types were synovial sarcoma (100%) ovarian (50–88%), NSCLC, endometrioid uterine adenocarcinoma (59–64%), cervical (25%), pancreatic (86–100%), colorectal (28–50%), esophageal (25–46%) and gastric carcinoma (27–58%) [5, 15, 17, 18, 20–24]. This evidence concerns the gene MSLN and gastric carcinoma.